Ventilation inhomogeneities in relation to standard lung function in patients with cystic fibrosis
- PMID: 15531750
- DOI: 10.1164/rccm.200407-948OC
Ventilation inhomogeneities in relation to standard lung function in patients with cystic fibrosis
Abstract
Based on serial lung function measurements performed in 142 children (68 males; 74 females) with cystic fibrosis (CF), prospectively evaluated over an age range of 6 to 20 years, we attempted to determine whether the lung clearance index (LCI) as a measure of ventilation inhomogeneities could be a discriminating factor of disease progression. Annual follow-up lung function measurements featuring FRC determined by whole-body plethysmography and multibreath nitrogen washouts, effective specific airway resistance, flow-volume curves, LCI, and gas exchange characteristics were analyzed by linear mixed-model analysis and Kaplan-Meier statistics. The earliest occurring and strongest factor of progression was the LCI, followed by maximal expiratory flow (MEF(50)) and FRC determined by plethysmography (p < 0.0001). Associations between onset of chronic Pseudomonas aeruginosa infection and CF transmembrane conductance regulator (CFTR) genotype with FEV(1) (p = 0.027) and FVC (p = 0.007) were identified. The study shows that the LCI predicts earlier in life and represented much better functional progression than FEV(1). Moreover, there is no single functional predictor of progression in CF, but aside from risk factors, such as onset of chronic P. aeruginosa infection and genotype, pulmonary hyperinflation, airway obstruction, and ventilation inhomogeneities are important pathophysiologic processes that should be evaluated concomitantly as determinants of lung progression in CF.
Comment in
-
Ventilation inhomogeneities in patients with cystic fibrosis: inappropriate reference data and errors?Am J Respir Crit Care Med. 2005 Sep 1;172(5):645; author reply 645-6. doi: 10.1164/ajrccm.172.5.954. Am J Respir Crit Care Med. 2005. PMID: 16120722 No abstract available.
Similar articles
-
Progression of pulmonary hyperinflation and trapped gas associated with genetic and environmental factors in children with cystic fibrosis.Respir Res. 2006 Nov 30;7(1):138. doi: 10.1186/1465-9921-7-138. Respir Res. 2006. PMID: 17137500 Free PMC article.
-
Effect of allergic bronchopulmonary aspergillosis on lung function in children with cystic fibrosis.Am J Respir Crit Care Med. 2006 Dec 1;174(11):1211-20. doi: 10.1164/rccm.200603-423OC. Epub 2006 Sep 7. Am J Respir Crit Care Med. 2006. PMID: 16959918
-
Early cystic fibrosis lung disease detected by bronchoalveolar lavage and lung clearance index.Am J Respir Crit Care Med. 2012 Apr 15;185(8):862-73. doi: 10.1164/rccm.201109-1631OC. Epub 2012 Feb 9. Am J Respir Crit Care Med. 2012. PMID: 22323305
-
Lung clearance index in the assessment of airways disease.Respir Med. 2009 Jun;103(6):793-9. doi: 10.1016/j.rmed.2009.01.025. Epub 2009 Feb 25. Respir Med. 2009. PMID: 19246184 Review.
-
Inert gas washout in preschool children.Paediatr Respir Rev. 2005 Dec;6(4):239-45. doi: 10.1016/j.prrv.2005.09.009. Epub 2005 Nov 9. Paediatr Respir Rev. 2005. PMID: 16298306 Review.
Cited by
-
Multiple-breath washout to detect lung disease in patients with inborn errors of immunity.ERJ Open Res. 2024 Mar 11;10(2):01019-2023. doi: 10.1183/23120541.01019-2023. eCollection 2024 Mar. ERJ Open Res. 2024. PMID: 38469376 Free PMC article.
-
Assessment of functional diversities in patients with Asthma, COPD, Asthma-COPD overlap, and Cystic Fibrosis (CF).PLoS One. 2024 Feb 20;19(2):e0292270. doi: 10.1371/journal.pone.0292270. eCollection 2024. PLoS One. 2024. PMID: 38377145 Free PMC article.
-
Efficacy and safety profile of elexacaftor-tezacaftor-ivacaftor triple therapy on cystic fibrosis: a systematic review and single arm meta-analysis.Front Pharmacol. 2023 Dec 14;14:1275470. doi: 10.3389/fphar.2023.1275470. eCollection 2023. Front Pharmacol. 2023. PMID: 38186649 Free PMC article.
-
Functional Predictors Discriminating Asthma-COPD Overlap (ACO) from Chronic Obstructive Pulmonary Disease (COPD).Int J Chron Obstruct Pulmon Dis. 2022 Oct 21;17:2723-2743. doi: 10.2147/COPD.S382761. eCollection 2022. Int J Chron Obstruct Pulmon Dis. 2022. PMID: 36304971 Free PMC article.
-
Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for F508del and a Minimal Function Mutation: A Phase 3b, Randomized, Placebo-controlled Study.Am J Respir Crit Care Med. 2022 Dec 1;206(11):1361-1369. doi: 10.1164/rccm.202202-0392OC. Am J Respir Crit Care Med. 2022. PMID: 35816621 Free PMC article. Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
